Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa.

Collie, Shirley; Nayager, Jiren; Bamford, Lesley; Bekker, Linda-Gail; Zylstra, Matt; Gray, Glenda

Collie, Shirley; Nayager, Jiren; Bamford, Lesley; Bekker, Linda-Gail; Zylstra, Matt; Gray, Glenda.

Collie S; Discovery Health, Sandton, South Africa.
Nayager J; Discovery Health, Sandton, South Africa.
Bamford L; National Department of Health, Pretoria, South Africa.
Bekker LG; Desmond Tutu HIV Foundation, Cape Town, South Africa.
Zylstra M; Discovery Health, Sandton, South Africa.
Gray G; South African Medical Research Council, Cape Town, South Africa glenda.gray@mrc.ac.za.

N Engl J Med ; 387(14): 1332-1333, 2022 10 06.

Article in English | MEDLINE | ID: covidwho-2028762

Subject(s)

BNT162 Vaccine; COVID-19; SARS-CoV-2; BNT162 Vaccine/immunology; BNT162 Vaccine/therapeutic use; COVID-19/epidemiology; COVID-19/etiology; COVID-19/prevention & control; Humans; SARS-CoV-2/genetics; SARS-CoV-2/immunology; South Africa/epidemiology; Vaccination; Vaccine Efficacy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / BNT162 Vaccine Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Africa Language: English Journal: N Engl J Med Year: 2022 Document Type: Article Affiliation country: NEJMc2210093

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google